Sinovac Biotech (SVA) Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine

Go back to Sinovac Biotech (SVA) Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine

Sinovac Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine

February 8, 2021 7:30 AM EST

BEIJING--(BUSINESS WIRE)-- Sinovac Biotech Ltd. (NASDAQ: SVA) (Sinovac or the Company), a leading provider of biopharmaceutical products in China, today announced that the China National Medical Products Administration (NMPA) has granted a conditional marketing authorization (CMA) to Sinovac for CoronaVac, Sinovacs COVID-19 vaccine in individuals aged 18 and above.

Sinovac began rolling submission to the NMPA since September 2020 and the NMPA carried out rolling reviews when the submission was made. As of February 4, 2021, the Company made more than 40 submissions to the NMPA. After obtaining the preliminary efficacy results, Sinovac formally filed for application of a... More